Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $16.0 million.

  • Mirum Pharmaceuticals' Other Non-Current Liabilities rose 302.34% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 302.34%. This contributed to the annual value of $2.5 million for FY2024, which is 34.81% down from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Other Non-Current Liabilities stood at $16.0 million, which was up 76.51% from $9.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $141.7 million in Q1 2023 and a low of $7,000 during Q3 2023.
  • Over the past 3 years, Mirum Pharmaceuticals' median Other Non-Current Liabilities value was $4.0 million (recorded in 2024), while the average stood at $18.1 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Other Non-Current Liabilities soared by 420,823.33% in 2021 and then crashed by 99.99% in 2023.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Other Non-Current Liabilities stood at $129.9 million in 2021, then grew by 8.03% to $140.4 million in 2022, then plummeted by 97.26% to $3.8 million in 2023, then slumped by 34.81% to $2.5 million in 2024, then soared by 302.34% to $16.0 million in 2025.
  • Its last three reported values are $16.0 million in Q3 2025, $9.1 million for Q2 2025, and $13.9 million during Q1 2025.